Q2 FY27 — 3 Nov 2026
Anlon Healthcare Limited Q2 FY27
Anlon Healthcare demonstrated strong operational growth in Q2 FY27, with consolidated revenue doubling YoY to ₹105.61 crores and H1 FY27 performance exceeding the full-year FY26 topline. EBITDA margins rebounded sharply to 23.9% from 17.8% in Q1 FY27, driven by successful price revisions to absorb elevated raw material costs. The company is actively executing a ₹130 crore greenfield expansion at Rajkot to add 1,200 MTPA capacity by Q1 FY28, while expanding into finished dosages, biologics, and medical devices.
Read the full call






